Checkpoint Controls and Targets in Cancer Therapy
There is no question that loss of cell cycle checkpoint regulation is an intrinsic characteristic of cancer. However, many tumors retain parallel checkpoint pathways that are activated by antitumor agents and facilitate therapeutic response. Failures in these therapy-linked checkpoint controls are c...
| Corporate Author: | |
|---|---|
| Other Authors: | |
| Format: | Electronic |
| Language: | English |
| Published: |
Totowa, NJ :
Humana Press,
2009.
|
| Edition: | 1. |
| Series: | Cancer Drug Discovery and Development
|
| Subjects: | |
| Online Access: | https://ezaccess.library.uitm.edu.my/login?url=http://dx.doi.org/10.1007/978-1-60761-178-3 |
Table of Contents:
- Evasion of G1 checkpoints in Cancer
- Distinct Pathways Involved in S-Phase Checkpoint
- Mechanisms of G2 Phase Arrest in DNA Damage-Induced Checkpoint Response
- Centrosomes in Checkpoint Response
- Interplay of 14-3-3 Family of Proteins with DNA Damage-Regulated Molecules in Checkpoint Control
- Chromatin Modifications and Orchestration of Checkpoint Response in Cancer
- DNA Damage Response and the Balance Between Cell Survival and Cell Death
- Dysfunction of the RB Retinoblastoma Gene in Cancer
- G1 Phase Cyclins in Cancer Development and Progression
- The BRCA1/2 Pathway Prevents Some Leukemias and Lymphomas in Addition to Breast/Ovarian Cancers: Malignancies that Overcome Checkpoint Controls
- Regulation of p53 Activity and Associated Checkpoint Controls
- The importance of p53 signaling in the response of cells to checkpoint inhibitors
- Targeting p21-Dependent Pathways for Cell Death in Cancer Therapy
- p27Kip1 as a Biomarker and Target for Treatment of Cancer
- Targeting Cyclin-Dependent Kinases with Small molecule inhibitors
- Chk1/Chk2 as checkpoint targets
- Targeting Cdc25 phosphatases in cancer therapy.-.